- Home
- DEA vs ARDX Comparison
DEA vs ARDX Comparison
Compare DEA & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- ARDX
- Stock Information
- Founded
- DEA 2011
- ARDX 2007
- Country
- DEA United States
- ARDX United States
- Employees
- DEA N/A
- ARDX N/A
- Industry
- DEA Real Estate Investment Trusts
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- DEA Real Estate
- ARDX Health Care
- Exchange
- DEA Nasdaq
- ARDX Nasdaq
- Market Cap
- DEA 1.0B
- ARDX 882.9M
- IPO Year
- DEA 2015
- ARDX 2014
- Fundamental
- Price
- DEA $21.96
- ARDX $5.97
- Analyst Decision
- DEA Hold
- ARDX Strong Buy
- Analyst Count
- DEA 5
- ARDX 9
- Target Price
- DEA $27.15
- ARDX $10.50
- AVG Volume (30 Days)
- DEA 475.8K
- ARDX 4.4M
- Earning Date
- DEA 08-05-2025
- ARDX 08-04-2025
- Dividend Yield
- DEA 8.20%
- ARDX N/A
- EPS Growth
- DEA N/A
- ARDX N/A
- EPS
- DEA 0.38
- ARDX N/A
- Revenue
- DEA $322,861,000.00
- ARDX $386,146,000.00
- Revenue This Year
- DEA $7.81
- ARDX $10.10
- Revenue Next Year
- DEA $8.60
- ARDX $32.38
- P/E Ratio
- DEA $58.08
- ARDX N/A
- Revenue Growth
- DEA 7.93
- ARDX 83.88
- 52 Week Low
- DEA $19.33
- ARDX $3.21
- 52 Week High
- DEA $36.31
- ARDX $7.18
- Technical
- Relative Strength Index (RSI)
- DEA 43.39
- ARDX 82.99
- Support Level
- DEA $21.74
- ARDX $4.08
- Resistance Level
- DEA $22.44
- ARDX $5.31
- Average True Range (ATR)
- DEA 0.48
- ARDX 0.24
- MACD
- DEA -0.03
- ARDX 0.12
- Stochastic Oscillator
- DEA 26.72
- ARDX 97.93
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.